New migraine treatment has fewer side effects
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new treatment for migraine that is as effective as existing drugs but with fewer side effects will bring fresh hope to millions of sufferers, scientists said yesterday.
Improved understanding of the mechanism that causes the brain to over-react to stimuli has led to the development of a drug that works in a different way from existing treatments.
Migraine affects an estimated six million people in Britain – 15 per cent of the adult population – and runs in families. It is caused by an "oversensitive" brain which reacts to triggers such as fatigue, hunger, stress or the weather with a throbbing, one-sided headache, often accompanied by nausea and visual disturbances. It affects three times more women than men.
The new drug, called telcagepant, is a rescue treatment that interrupts the sequence of chemical reactions in the brain that cause the migraine at a different point from existing drugs.
A final trial of the drug, published in The Lancet today, showed it reduced pain and was better at preventing the return of the migraine over 24 hours than zolmitriptan, an existing triptan drug. However, the improvement was not statistically significant.
The main advantage of telcagepant was reduced side effects. Triptans can cause a tight chest and throat, dizziness, numbness of skin and is thought to have a potential constricting effect on the blood vessels. As a result, patients with heart disease and high blood pressure are advised not to take it.
Telcagepant does not appear to have the same vasoconstricting (blood vessel narrowing) properties, but heart patients were excluded from the trial. The study was conducted among 1,380 patients in 81 hospitals in the US and Europe, led by Tony Ho of Merck Research Laboratories, Philadelphia.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments